{"id":197,"date":"2025-09-05T00:54:47","date_gmt":"2025-09-05T00:54:47","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=197"},"modified":"2025-09-05T04:16:13","modified_gmt":"2025-09-05T04:16:13","slug":"china-bd-2025-hengrui-and-braveheart-bio-achieved-a-1-billion-usd-license-on-myosin-inhibitor-hrs-1893","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/197.html","title":{"rendered":"[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893"},"content":{"rendered":"\n<p>Announced Date: 2025-09-05 (September 5, 2025)<\/p>\n\n\n\n<p>Asset Name: HRS-1893<\/p>\n\n\n\n<p>Licensor: Jiangsu Hengrui Pharmaceuticals (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Braveheart Bio, Inc. (US) \uff08NewCo\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: Myosin inhibitor<\/p>\n\n\n\n<p>Potential Indication:  obstructive hypertrophic cardiomyopathy (oHCM)<\/p>\n\n\n\n<p>Current Stage: Phase III<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Hengrui will grant Braveheart Bio the exclusive rights to develop, manufacture, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macao, and Taiwan.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp;$65 million ($32.5 million in cash, and an equivalent of $32.5 million in Braveheart Bio company stock ) ,<\/p>\n\n\n\n<p>Near term payments of $10 billion \uff08after technology transfer\uff09,<\/p>\n\n\n\n<p>Milestone payments up to &nbsp;$1.013 billion,<\/p>\n\n\n\n<p>Total up to $1.088 billion<\/p>\n\n\n\n<p>Royalties on net sales, &nbsp;tiered<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/stockmc.xueqiu.com\/202509\/600276_20250905_QW7Y.pdf\">600276_20250905_QW7Y.pdf (xueqiu.com)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-09-05 (September 5, 2025) Asset Name: HRS-1893 Licensor: Jiangsu Hengrui Pharmaceuticals (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/197.html\"><span class=\"screen-reader-text\">[China BD 2025] Hengrui and Braveheart Bio (NewCo) enters a 1 billion USD license on Myosin inhibitor HRS-1893<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,5],"tags":[],"class_list":["post-197","post","type-post","status-publish","format-standard","hentry","category-china-license-out","category-newco"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=197"}],"version-history":[{"count":3,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/197\/revisions"}],"predecessor-version":[{"id":203,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/197\/revisions\/203"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}